Get the Stockscreener App
3.90
3.23%
-0.13
Pre-market:
3.90
Phathom Pharmaceuticals Inc stock is traded at $3.90, with a volume of 1.19M.
It is down -3.23% in the last 24 hours and down -37.40% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$4.03
Open:
$4
24h Volume:
1.19M
Relative Volume:
1.01
Market Cap:
$322.42M
Revenue:
-
Net Income/Loss:
$-297.11M
P/E Ratio:
-0.7514
EPS:
-5.19
Net Cash Flow:
$-216.95M
1W Performance:
-15.77%
1M Performance:
-37.40%
6M Performance:
-74.87%
1Y Performance:
-56.52%
1-Day Range:
$3.87
$4.155
1-Week Range:
$3.87
$5.09
52-Week Range:
$3.81
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
3.90 | 322.42M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Alliancebernstein L.P. Has $370,000 Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
The Goldman Sachs Group Cuts Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $10.00 - Defense World
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge - simplywall.st
Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years ago - Yahoo Finance
Phathom Pharmaceuticals appoints Ted Schroeder to board By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals appoints new board member By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals appoints new board member - Investing.com
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of D - GuruFocus
Phathom Pharmaceuticals Appoints Theodore Schroeder to Board - TipRanks
Phathom Pharmaceuticals Appoints Ted Schroeder To Its Board Of Directors - marketscreener.com
Phathom Pharmaceuticals appoints Ted Schroeder to board - Investing.com
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors - GlobeNewswire
Strategic Win: Phathom Taps 30-Year Pharma Veteran to Drive VOQUEZNA Commercial Success - Stock Titan
Vanguard Group Inc. Increases Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Wellington Management Group LLP Reduces Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals’ (PHAT) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
9,100 Shares in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Acquired by KLP Kapitalforvaltning AS - Defense World
Phathom Pharmaceuticals stock hits 52-week low at $4.07 By Investing.com - Investing.com Canada
Phathom Pharmaceuticals stock hits 52-week low at $4.07 - Investing.com
Phathom Pharmaceuticals CFO Molly Henderson sells $16,739 in stock By Investing.com - Investing.com Canada
Phathom Pharmaceuticals CFO Molly Henderson sells $16,739 in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - Yahoo Finance
Commonwealth Equity Services LLC Acquires 40,362 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - simplywall.st
Analysts Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) PT at $22.17 - Defense World
Guggenheim Reiterates “Buy” Rating for Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
Needham & Company LLC Reaffirms Buy Rating for Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (PHAT) - Seeking Alpha
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
GI Disease Leader Phathom Takes Center Stage at Major Healthcare Conference - Stock Titan
Craig-Hallum Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT) - The Globe and Mail
Needham Remains a Buy on Phathom Pharmaceuticals (PHAT) - The Globe and Mail
Critical Analysis: Quoin Pharmaceuticals (NASDAQ:QNRX) & Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
When (PHAT) Moves Investors should Listen - news.stocktradersdaily.com
Change at the top for Phathom as Basta replaces Curran - biocentury.com
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Phathom's New CEO Stakes Future on Stock Price and Revenue Goals - Stock Titan
Phathom Pharmaceuticals Announces Leadership Transition in 2025 - TipRanks
Phathom Pharmaceuticals Names Steven Basta CEO - MarketScreener
Phathom Pharmaceuticals Announces Leadership Succession - MarketScreener
Phathom Pharmaceuticals appoints new CEO - Investing.com
Phathom Pharmaceuticals appoints new CEO By Investing.com - Investing.com UK
Kenan Thompson partners with Phathom for GERD treatment By Investing.com - Investing.com Philippines
Kenan Thompson partners with Phathom for GERD treatment - Investing.com India
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan) - The Manila Times
Actor and Comedian Kenan Thompson Teams Up with Phathom - GlobeNewswire
SNL Legend Kenan Thompson Reveals Personal GERD Battle, Champions New Breakthrough Treatment - Stock Titan
Virtu Financial LLC Acquires New Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Raymond James Financial Inc. Takes Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Charles Schwab Investment Management Inc. Has $2.87 Million Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):